How Generic Drug Manufacturers Face Medicaid Inflation Penalties Without Actually Raising Prices

This white paper examines how the Medicaid Drug Rebate Program's inflation penalty can trigger rebate obligations for generic manufacturers even when they haven't increased prices beyond inflation, due to purchasing pattern shifts, seasonal fluctuations, or commodity market dynamics. The analysis details five scenarios where AMP increases occur mechanically rather than through deliberate price hikes, creating financial pressure on generics manufacturers operating on thin margins. For MCO pharmacy programs and state Medicaid finance teams, this explains important dynamics affecting generic drug availability and rebate calculations.

Pharmacy · Managed Care · Finance

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere